Stem Cell Therapeutics, Medicon receive approval for phase 1 trial of NTx-265 in stroke patients

By Angela McDaniels

Seattle, Nov. 9 - Stem Cell Therapeutics Corp. and Medicon AS said they have received approval to begin the phase 1 clinical study of Stem Cell's NTx-265 for the treatment of stroke.

The approval was granted by the Danish Medicines Agency and the Institutional Review Board.

The trial is designed to evaluate the uptake and distribution into the body of two currently marketed drugs that are effective in non-clinical models of stroke, the company said.

Stem Cell Therapeutics also has a phase 2 trial planned to evaluate safety and efficacy of NTx-265 therapy in stroke patients. Now that formal approval has been received, the company said it will begin screening trial subjects soon.

Medicon is drug development company based in Birkerod, Denmark.

Stem Cell Therapeutics is a biotechnology company based in Calgary, Alta., that develops technologies that use stem cells for the treatment of neurodegenerative conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.